<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-118397</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Initial antiretroviral treatment in human immunodeficiency virus-infected patients in Spain: Decisions made in relation to particular immunovirological characteristics (PERFIL-es study)</dc:title>
<dc:description xml:lang="en">Introduction: The purpose of Per&amp;#64257;l-es study was to identify the proportion of patients starting ARV treatment based on NNRTIs or PI/r, and to identify the variables involved in the therapeutic decision-makingin standard clinical practice. Methods: An observational restrospective study performed in 65 Spanish hospitals. Results: Was a total of 1,687 starts: 53% with NNRTI-based regimen and 42% with PI/r, and of the642 patients analyzed, 72% had a CD4 count &lt; 350 cells/l. Conclusion: The initiation of ARV treatment is still late in Spain. NNRTIs are the more frequent choice, although PI/r plays an important role (AU)</dc:description>
<dc:creator>Viciana , Pompeyo</dc:creator>
<dc:creator>Palazuelos , Marta</dc:creator>
<dc:creator>Ocampo, Antonio</dc:creator>
<dc:creator>Ledesma , Francisco</dc:creator>
<dc:creator>Hevia, Henar</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: El objetivo del estudio Perfil-es era conocer, en la práctica clínica, la proporción de TARV de inicio basado en ITINAN o IP/r e identificar los factores implicados en la decisión terapéutica. Métodos Estudio observacional, retrospectivo en 65 hospitales. Resultados Se iniciaron 1.687 TARV: un 53% basado en ITINAN y un 42% en IP/r. Se analizaron 642 pacientes. El 72% presentaba un recuento de CD4 &lt; 350 células/&amp;#956;l. Conclusión En España el TARV de inicio sigue siendo tardío. Los ITINAN son la elección más frecuente aunque los IP/r desempeñan un importante papel (AU)</dc:description>
<dc:source>Enferm Infecc Microbiol Clin;32(2): 93-95, feb. 2014. ilus</dc:source>
<dc:identifier>ibc-118397</dc:identifier>
<dc:title xml:lang="es">Tratamiento antirretroviral de inicio en pacientes infectados por el virus de la inmunodeficiencia humana en España: decisiones con relación a características inmunovirológicas específicas (estudio PERFIL-es)</dc:title>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d32626^s22000</dc:subject>
<dc:subject>^d35395^s22045</dc:subject>
<dc:subject>^d29363^s22057</dc:subject>
<dc:subject>^d38332^s22000</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d30696^s22000</dc:subject>
<dc:subject>^d19291</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d32994^s22000</dc:subject>
<dc:type>article</dc:type>
<dc:date>201402</dc:date>
</metadata>
</record>
</ibecs-document>
